Why we don't use online VCS testing

Visual Contrast Sensitivity was Dr. Shoemaker's first biomarker for biotoxin illness. A foundational discovery, it gave clinicians an objective screening tool for the first time. With calibrated equipment and controlled lighting, clinical VCS is a reproducible marker of visual pathway dysfunction. In the clinic, it remains a valuable piece of the diagnostic picture.

The problem is what happens when you move it to a laptop screen at home. No published study has validated VCS for digital administration on consumer screens. MoldCo built its telehealth evaluation around symptom clusters and blood biomarkers because those tools work reliably outside a controlled clinical environment.

The appeal of a free online test

If you've searched for a way to screen yourself for mold illness, you've found the online VCS test. Ten minutes on your laptop. No appointment, no blood draw, no waiting room.

The problem is what happens after.

A failed result doesn't tell you the cause. Cataracts, glaucoma, Lyme disease, severe diabetes, medication side effects, and visual fatigue can all reduce contrast sensitivity. VCS can't distinguish between them. And on the other side, Shoemaker and House (2006) published a false negative rate of about 8% under controlled clinical conditions. That's 1 in 12 people with confirmed mold illness who passed the test. Clinicians working with CIRS patients routinely report higher false negative rates in practice.

On an uncalibrated consumer screen, the miss rate is likely worse.

Without clinical context, a positive result can send someone down the wrong path, and a negative result can provide false reassurance. The test wasn't designed to be interpreted alone — and on a consumer screen, the margin for error grows.

"Exposed to high levels of toxic mold for months in a rental home. Brain fog, fatigue, sick more often, working memory clobbered. Treatment with MoldCo has been a huge blessing, finally recovering. If not for them mold wouldn't even be on my radar as a potential cause. Most doctors aren't trained to diagnose it." -- MoldCo patient

If your mold exposure symptoms match several of the 13 CIRS symptom clusters, that pattern matters more than any single screening test.

What clinical VCS actually requires

In the clinic, VCS uses an APT VCS tester or a calibrated display set to exactly 85 cd/m2 (candelas per square meter). The test is administered at standardized viewing distances: 14 inches for near-vision acuity screening and 18 inches for the VCS test itself. Controlled ambient lighting is required. Before testing, a certified provider confirms the patient has at least 20/50 visual acuity in each eye.

In Shoemaker and House's 2006 study, 100% of 26 confirmed patients from water-damaged buildings showed VCS deficit at baseline under those conditions. That's a real signal when every variable is locked down.

The clinical testing protocol requires ANSI and ISO conformity for contrast sensitivity function (CSF) measurement. Specific spatial frequencies, calibrated to the display. Progressive difficulty. Trained examiner scoring.

Now picture the same test on your laptop. The screen brightness isn't calibrated. Pixel density varies between a MacBook Retina display and a 5-year-old desktop monitor. Your room lighting might be an overhead fluorescent or a lamp behind you creating glare. You're sitting at whatever distance feels comfortable, not the standardized 14-to-18-inch range. Nobody checked your visual acuity. The test takes under 10 minutes with no clinical oversight.

The result tells you something. But it may tell you more about your screen or your lighting conditions than your visual cortex.

Original VCS validation was conducted on CRT monitors. Research on LCD display calibration shows newer screens introduce their own variability in contrast reproduction. Screen-based contrast testing adds uncontrolled variables from display technology, viewing geometry, and ambient illumination. Even validated smartphone-based contrast tests like K-CS were developed and tested under controlled clinical conditions, not home environments. ISCEV guidelines for clinical vision instruments show the calibration rigor standardized testing demands. Consumer devices can't replicate it.

The study that would validate or invalidate online VCS simply hasn't been done. That matters — not because VCS lacks clinical value, but because the online version hasn't earned the same confidence.

Why clusters beat VCS-inclusive screening

VCS was first published by Shoemaker (2001) as a screening tool for Pfiesteria, an estuarine neurotoxin. It was the first objective biomarker in what would become a much larger diagnostic framework. By 2006, Dr. Shoemaker's diagnostic criteria included VCS as one of six biomarkers; a patient needed three of six abnormal to meet the CIRS case definition. VCS was always part of a panel, not a standalone diagnostic. Over the following two decades, it continued as one component of the Shoemaker Protocol, used alongside exposure history and symptom roster as one of three screening evaluations.

The American College of Medical Toxicology (ACMT) 2025 position statement on mold-related inhalation exposures doesn't include VCS in its recommended diagnostic workup. The CDC/NIOSH used VCS as a research tool for comparing employees at water-damaged versus control buildings but didn't endorse it as a standalone diagnostic.

Here's the data that shaped our decision.

In McMahon 2017 (Medical Research Archives), symptom cluster analysis achieved 98.4% sensitivity in adults when 8 or more of 13 clusters were present. The VCS-inclusive 3-screen battery (symptom roster, VCS, and anti-gravity muscle testing) achieved 37.4-43.1% sensitivity depending on age group.

For a telehealth practice where we can't control the testing environment, clusters give us the strongest signal.

"MoldCo has been the only team able to give me clear answers, real science, and compassionate support. Their testing process is straightforward, their reports are actionable, and their guidance has genuinely changed the way I understand and manage my health." -- MoldCo patient

MoldCo's intake covers all 13 symptom clusters, verified water-damaged building exposure, and exclusion criteria. It's built for accuracy in a telehealth context, where we can't control your screen but we can control the questions we ask. You can start the process with a free Signs Questionnaire before ever booking a call.

What your results actually mean

If you've already taken an online VCS test, here's what you can and can't draw from it.

If you failed: The test detected reduced contrast sensitivity under those specific conditions. It can't identify the cause. Cataracts, glaucoma, Lyme disease, severe diabetes, medication side effects, and visual fatigue can all produce the same result. A failed online VCS isn't a mold illness diagnosis, but it may be worth discussing with a clinician who can interpret it alongside your full history.

If you passed: Even clinical VCS has a published false negative rate of about 8% (Shoemaker 2006). One in 12 people with confirmed mold illness pass the test under controlled conditions. On an uncalibrated consumer screen, the miss rate is likely higher. A passing score doesn't rule anything out.

If you've been tracking over time: Serial testing on consumer screens compounds the variables. What looks like improvement or decline may reflect your testing environment (screen brightness, room lighting, time of day, fatigue) rather than your health.

Blood biomarkers like MSH, TGF-beta1, and MMP-9 measure the inflammatory cascade directly. MoldCo's Starter Health Panel ($99 through LabCorp) gives you objective numbers that aren't affected by testing conditions.

Beyond VCS: where diagnostics have moved

The diagnostic toolkit has expanded significantly since VCS opened the door in 2001. Blood biomarkers like MSH, TGF-beta1, MMP-9, and C4a quantify what's happening in your immune system directly. Transcriptomic profiling adds another layer of precision. The trajectory is toward more tools, not fewer. VCS remains part of the clinical picture for providers with calibrated equipment.

The gap is in digital access. No one has validated VCS for the way most people encounter it today: on a laptop, without clinical oversight. When someone asks "Is online VCS reliable?", the honest answer is: we don't know yet, because the validation study hasn't been done.

MoldCo chose to build its remote evaluation on tools that work reliably outside a clinic: symptom clusters and blood biomarkers. Clinical VCS continues to serve providers who can administer it properly. Our CIRS treatment roadmap reflects that choice.

"With MoldCo, I actually got to the root cause. I'm so glad that I trusted my gut to dig deeper into what was going on." -- MoldCo patient

Is online VCS testing reliable for mold illness screening?

No published study has validated VCS for digital administration on consumer screens. Clinical VCS requires calibrated display luminance, standardized viewing distances (14" for acuity, 18" for VCS), and controlled lighting. A laptop can't replicate those conditions. An online result may reflect your testing setup more than your visual function.

Why doesn't MoldCo offer VCS testing?

MoldCo's intake process (symptom cluster review, verified exposure history, and exclusion criteria) is designed for telehealth, where we can't control testing equipment. In McMahon 2017, cluster analysis reached 98.4% sensitivity in adults, making it the strongest screening tool available in a remote setting.

I failed an online VCS test. Does that mean I have mold illness?

A failed online VCS tells you something is affecting your contrast sensitivity under those specific conditions. It can't tell you the cause: cataracts, glaucoma, Lyme disease, severe diabetes, and medication side effects can all reduce contrast sensitivity. The result is a data point, not a diagnosis. A clinician can help you interpret it in context.

I passed an online VCS test. Can I rule out mold illness?

No. Even clinical VCS has a published false negative rate of approximately 8% (Shoemaker 2006). On an uncalibrated consumer screen, the miss rate is likely higher. If your symptoms match multiple CIRS clusters, that pattern matters regardless of a single screening result.

What should I do instead of online VCS testing?

Start with a validated symptom assessment. MoldCo's free Signs Questionnaire covers all 13 CIRS symptom categories and is designed for the digital context. If your results suggest further evaluation, a provider call and blood biomarker panel give you objective data you can act on.

If your symptoms line up and the exposure history fits, the next step is objective data you can act on.

Start your evaluation | Take the free Signs Questionnaire

Any health-related claims made on this site have not been evaluated by the Food and Drug Administration (FDA). The information provided on this site is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. MoldCo assumes no responsibility or liability for any errors or omissions in the content of the references, nor for any actions taken in reliance thereon.